A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions

Darbà, JosepRamírez, GabrielaGarcía-Rivero, Juan L.Mayoralas, SagrarioPascual, José FranciscoRoger, AlbertVargas, DiegoBijedic, Adi2017-03-022017-03-022016-091178-6981https://hdl.handle.net/2445/107753To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...10 p.application/pdfengcc-by-nc (c) Darbà, Josep et al., 2016http://creativecommons.org/licenses/by-nc/3.0/esAdministració de medicamentsAsmaMalalties pulmonars obstructives cròniquesTractament tèrmicEconomia de la salutAdministration of drugsAsthmaChronic obstructive pulmonary diseasesHeat treatmentMedical economicsA budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regionsinfo:eu-repo/semantics/article6683972017-03-02info:eu-repo/semantics/openAccess27660476